<DOC>
	<DOCNO>NCT01612299</DOCNO>
	<brief_summary>Primary objective : A . To evaluate effect Zortress® versus standard immunosuppression therapy progression CAC evidence change Agatston score baseline 6 , 12 month renal transplantation patient . B . To investigate progression CAC patient undergo renal transplantation within study period . Secondary objective : 1 . To evaluate renal transplantation effect Zortress® versus standard immunosuppression therapy bone mass evidence change quantitative compute tomography ( QCT ) dual energy X-ray absorptiometry ( DXA ) . 2 . To evaluate renal transplantation effect Zortress® versus standard immunosuppression therapy activity bone form resorb cell evidence change bone histology . 3 . To evaluate renal transplantation effect Zortress® versus standard immunosuppression therapy biochemical parameter bone turnover evidence change serum Parathyroid Hormone ( PTH ) , Bone-Specific Alkaline Phosphatase ( BSAP ) , Tartrate-Resistant Acid Phosphatase ( TRAP ) , Sclerostin , Receptor Activator Nuclear factor Kappa B Ligand ( RANKL ) , Osteoprotegerin ( OPG ) , , serum CTX ( C-terminal telopeptide type 1 collagen ) , urinary NTX ( N-terminal cross link telopeptide ) . 4 . To evaluate renal transplantation effect Zortress® versus standard immunosuppression therapy cardiovascular event , graft rejection patient survival .</brief_summary>
	<brief_title>Effects Zortress® + Tacrolimus vs. Standard Immunosuppression Progression Coronary Artery Calcifications Bone Disease de Novo Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>De novo renal transplant recipient ( decease living donor ) 1870 year age Willingness participate study comply study requirement evidence sign IRBapproved informed consent Enrollment Previous solid organ transplant Known hypersensitivity study drug , class , excipients Recipients investigational drug within 30 day transplant Any abnormal physical laboratory finding clinical significance would interfere conduct study Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use medically approve mean contraception Randomization Platelet count &lt; 75,000/mm White blood cell count &lt; 2,000/mm³ Hypercholesterolemia ( &gt; 400 mg/dL ) hypertriglyceridemia ( &gt; 500 mg/dL ) despite lipidlowering therapy Presence clinically significant infection require IV antibiotic Positive serum HCG ( woman childbearing potential ) Spot urine protein creatinine ratio ( UPr/Cr ) ≥ 0.5 Any biopsyconfirmed acute rejection since transplant Baseline CAC score &lt; 100 baseline reading</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>